Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Costco Wholesale Corporation (COST) vs Summit Therapeutics Inc (SMMT) Price & Performance

Costco Wholesale CorporationTrade
Summit Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Costco Wholesale Corporation vs Summit Therapeutics Inc — how do they compare? Costco Wholesale Corporation trades at $948.07 (market cap $418.79B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Costco Wholesale Corporation is far larger — about 34.7× Summit Therapeutics Inc's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.

COSTSMMT
Market Cap
$418.79B$12.06B
Sector
Consumer StaplesHealth
52-Week High
$1.09K$26.98
52-Week Low
$849.63$12.55
Enterprise Value
$406.93B$11.39B
Dividend Yield
0.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Costco Wholesale Corporation

Costco Wholesale Corporation (COST) trades at $948.43, down 0.45% on the day, with technical indicators signaling a bearish trend amid neutral oscillators. The stock shows strong fundamentals with revenue growth to $275.24 billion in 2025 and consistent earnings beats, though it missed Q1 2026 estimates. Recent news highlights membership fee hikes and robust March sales, while analyst consensus remains bullish with a $1,120 price target.

The outlook for COST is positive due to steady revenue growth and high analyst confidence, but risks include elevated valuation multiples and competitive pressures. Investment opportunity lies in its scalable business model and membership-driven profits, though investors should monitor earnings consistency and macroeconomic impacts on consumer spending.

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Costco Wholesale Corporation

The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet

Read more on COST

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT